Amryt Pharma's ) Joe Wiley talks to Proactive New York's Christine Corrado about their latest record Q3 2020 Results.
The results have lead to the full year guidance being raised which Wiley puts down to two launched commercial assents, metreleptin and lomitapide.
Wiley talks through these results which show 19% YoY revenue growth in the quarter to $49.3m, with a rise in full year revenue guidance to $180m - $182m.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE